Ligand partner travere therapeutics announces achievement of interim proteinuria endpoint in the ongoing phase 3 duplex study of sparsentan in focal segmental glomerulosclerosis

San diego--(business wire)--ligand pharmaceuticals incorporated (nasdaq: lgnd) partner travere therapeutics, inc. (nasdaq: tvtx) today announced that their ongoing pivotal phase 3 duplex study of sparsentan in focal segmental glomerulosclerosis (fsgs) achieved its pre-specified interim fsgs partial remission of proteinuria endpoint (fpre) after 36 weeks of treatment. sparsentan, an investigational product candidate, demonstrated a statistically significant response on fpre compared to the activ
TVTX Ratings Summary
TVTX Quant Ranking